drugset
drugset / Trial / NCT05936489

Plasma Pharmacokinetics and Safety of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With Presbyopia

NCT05936489 ↗

Phase 1 Completed 30 enrolled LENZ Therapeutics, Inc ORA, Inc. · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a single-center, open-label, randomized study to assess the plasma pharmacokinetic profile of LNZ101 and LNZ100.

Timeline

Start
2023-07-06
Primary completion
2023-10-03
Completion
2023-10-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Aceclidine Small molecule 1.75 % Topical
Subject Brimonidine Small molecule — Topical

Indications

presbyopia